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Abstract
BACKGROUND: At present, there is no pharmacological therapy that can cure Alzheimer’s disease. Treatment is 
only limited to preventing progression and controlling risk factors that worsen Alzheimer’s. Medium-chain triglycerides 
(MCT) are nutritional therapies that are being studied to prevent the progression of Alzheimer’s disease.
AIM: This study aims to see the effect of giving MCT to the value of percentage alternation Y-maze test and serum 
Aβ-42 levels as a marker of Alzheimer’s disease.
MATERIALS AND METHODS: This study is an experimental study using postp-test control group design. Samples 
from this study were 30 Sprague Dawley rats which were divided into positive control groups, negative controls, 
and three treatment groups. Positive control group and treatment were induced by Alzheimer’s by ovariectomy and 
d-galactose. After induction, MCT were given to the treatment group for 6 weeks. After treatment, the levels of Aβ-42 
serum were examined by ELISA and cognitive function was examined by Y-maze. After that, the data were analyzed 
by ANOVA. p < 0.05 was said to be statistically significant.
RESULTS: The results showed that this study was found a moderate relationship with a positive pattern. This means 
that the higher the percentage alternation value, the higher the level of Aβ-42 in serum which indicates that the higher 
the percentage alternation value, the higher the clearance of Aβ-42.
CONCLUSION: This study concluded that the group of rats given MCT has a serum Aβ-42 level higher than the 
group of rats that were not given MCT.
Edited by: Sinisa Stojanoski
Citation: Faradila F, Syafrita Y, Lipoeto NI. Relationship 
between Amyloid-beta 42 Levels and Y-maze Alternation 
Values in Sprague Dawley Alzheimer’s Induction Received 
Medium-Chain Triglycerides Therapy. Open Access Maced 
J Med Sci. 2020 Apr 14; 8(A):476-480. 
https://doi.org/10.3889/oamjms.2020.3243
Keywords: Aβ-42; Y-maze; Medium-chain triglycerides
*Correspondence: Faradila Faradila, Doctoral Student 
of Postgraduate Biomedical Science, Faculty of 
Medicine, Andalas University, Padang, Indonesia. 
E-mail: faradila1991@hotmail.com
Received: 18-Jun-2019;
Revised: 20-Feb-2020;
Accepted: 24-Feb-2020;
Copyright: © 2020 Faradila Faradila, Yuliarni Syafrita, 
Nur Indrawaty Lipoeto
Funding: This research did not receive any financial 
support
Competing Interests: The authors have declared that no 
competing interests exist.
Open Access: This is an open-access article distributed 
under the terms of the Creative Commons Attribution-
NonCommercial 4.0 International License (CC BY-NC 4.0)
Introduction
Medium-chain triglycerides (MCTs) are a fat 
that has a medium carbon chain length between C6 
and C12. Metabolically, MCT has its own uniqueness, 
that is, MCT does not enter the lymphatic system and 
peripheral circulation but is directly transported to the 
liver through the portal circulation, thus affecting the 
speed of metabolism to energy [1]. MCT metabolism in 
some ways is similar to carbohydrate metabolism and 
produces energy quickly through ketones production. 
Ketone is the compounds other than glucose that can 
be used by the brain to produce large and fast energy 
so it is very beneficial for the aging brain [2].
Ketone bodies can provide alternative energy 
in Alzheimer’s disease. Ketone bodies are usually 
produced from fat deposits as glucose substitutes in 
conditions of chronic hypoglycemia, such as during 
fasting, or when carbohydrate consumption is very low. 
In humans, ketone infusion can reduce the hormonal 
response to acute hypoglycemia and can improve 
cognitive function [3]. The mechanism of mediating 
ketone effects on cognitive functions is unclear. 
Rapid increases in some areas of cognitive function 
indicate that ketones can function as alternative fuels 
for brain neuron cells in MCI or Alzheimer’s patients. 
Alzheimer’s sufferers show defects in brain glucose 
metabolism that may arise from many factors, such 
as Aβ toxicity or from disorders of lipid homeostasis. 
Although acetyl-CoA is generally provided for the Krebs 
cycle of glycolysis, when glucose is not available, 
β-hydroxybutyrate can function as an alternative fuel 
for the brain [3].
Other findings in a study with Alzheimer’s 
induction rats revealed that beta-hydroxybutyrate 
maintains neuronal integrity and stability in rat 
hippocampus. Case reports in patients with chronic 
hypoglycemia due to insulin use who have impaired 
cognitive function, with beta-hydroxybutyrate infusion 
improved cognitive function in the control group and 
improved cognitive function related to hyperketonemia 
in a group of patients who experienced memory 
disorders. Brain imaging studies also show an 
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increase in cerebral blood flow by administering beta-
hydroxybutyrate in healthy subjects [4].
The pathophysiology of Alzheimer’s disease 
is not fully understood, but the cascade amyloid 
hypothesis is the most trusted hypothesis as the 
main cause. Senile plaques formed from amyloid-
beta (Aβ) deposits in tissue fluid around neurons. Aβ 
is a fraction of amyloid precursor protein (APP) which 
normally functions for growth and maintains neuron 
stability [5]. Amyloid protein precursor (APP) is a 
transmembrane glycoprotein found in neurons. APP in 
normal conditions will be described in the cell and cut 
by three enzymes, namely, α-secretase, β-secretase, 
and γ-secretase. APP described by the α-secretase will 
produce a non-toxic amyloid-beta (Aβ) fragment. APP 
which is described by β- secretase will be continued by 
cutting by γ-secretase so as to produce a soluble and 
neurotoxic Aβ. This toxic Aβ fragment called Aβ-42 is 
the most toxic form because its ability to form oligomers 
is faster than other fragments [6-8].
Aβ fragments can stick together and develop 
into a soluble deposit. Then, the deposit mixes with 
neuron cells to form plaque fibers that harden, solid, 
and insoluble, which are toxic to healthy neurons. Aβ is 
also thought to produce free radicals that interfere with 
the biochemical balance in neuron cells which disrupts 
neuronal metabolism [5]. In normal conditions, the amount 
of Aβ in brain tissue is strictly controlled, starting from 
the production process, secretion, and degradation of Aβ 
and cleaning of the brain parenchyma which is regulated 
by a very controlled process [5]. The Aβ concentration in 
the tissue is very important for maintaining the structure 
of this peptide, and increasing its concentration in the 
tissue is a possible cause of aggregation. Excessive Aβ 
production and disruption of clearance mechanisms are 
considered responsible for neuronal damage [9,10].
Materials and Methods
Experimental design
This research is a laboratory experimental 
study with a post-test only control group design. The 
samples from this study were 30 Sprague Dawley rats 
induced by d-galactose and ovariectomy to impair 
cognitive function. Furthermore, MCT was given. The 
inclusion criteria were 12-week-old female Sprague 
Dawley rats weighing 200–250 g who were healthy 
and who had suffered cognitive impairment. Exclusion 
criteria were those who experienced physical disabilities 
and died during the study.
The research subjects were divided into five 
groups: MCT group dose 1, dose 2, dose 3, positive 
control, and negative control. Treatment is given for 
6 weeks, after that, cognitive function assessment by 
Y-maze performed and ELISA of Aβ-42 levels serum 
using rat Aβ1-42 ELISA kit (e-EL-R 1402).
Dosage determination
The dose of MCT in human therapy is 
10–45 g/day. The dose for mice is obtained by 
converting a dose of 70 kg to a rat weighing 200 g. The 
conversion rate of a human with a body weight of 70 kg 
to a rat weighing 200 g is 0.018. In this study, MCT 
doses were given, namely, dose I = 0.018 × 15 g = 0.27 
g/day/200 g body weight and dose II = 0.018 × 30 g 
= 0.54 g/day/200 g body weight and dosage III 0.018 × 
45 g = 0.81 g/day/200 g body weight [11,12].
Examination of ELISA kit
Add 100 µL standard or sample to each well. 
Incubate for 90 min at 37°C. Remover of the liquid. 
Add 100 μL biotinylated detection Ab. Incubate for 1 h 
at 37°C. Aspirate and wash 3 times. Add 100 μL HRP 
Conjugate. Incubate for 30 min at 37°C. Aspirate and 
wash 5 times. Add 90 μL of substrate reagent. Incubate 
for 15 min at 37°C. Add 50 μL stop solution. Read at 
450 immediately. Calculation of results.
The Y-maze method
Testing is done in a Y-shaped maze with three 
identical arms at a 1200 angle from each other. After the 
introduction to the center of the maze, the animal is given 
free access to explore the three arms. If the animal chooses 
different from one it arrived from, this choice is called an 
alteration. This is considered the correct response while 
returning to the previous arm is considered an error. The 
total number of entries and orders is used to calculate 
the percentage of an alternation. This test is particularly 
useful in assessing hippocampal damage, quantifying the 
cognitive deficits in transgenic mice, and evaluating the 
effects of drugs on cognition [13].
Research ethics
This study was already passed the ethics 
clearance and has been approved by the Ethics 
Committee of the Faculty of Medicine, Andalas University, 
Padang with registration number: 530/KEP/FK/2018.
Results
From Figure 1, it can be seen that the positive 
control group has the lowest serum Aβ-42 level 
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compared to other groups. Low levels of Aβ-42 often 
associated with deteriorating cognitive function.
Table 1: Serum Aβ-42 levels
Group n Mean±SD Minimum Maximum
Negative control (K-) 6 7168.78 ± 2056.38 4798.67 9897.78
Positive control (K+) 6  2788.21 ± 1832.91 1190.47 5665.97
Dose 1 6 7123.92 ± 1629.40 5172.51 9419.26
Dose 2 6 6002.42 ± 1561.54 3901.47 8492.16
Dose 3 6 6012.39 ± 1169.93 4918.30 7535.14
From Figure 2, it can be seen that the positive control 
group has the lowest percentage of alternation Y-maze 
compared to other groups where the positive control 
group has a percentage alternation value below 50%. 
It means that the positive control group has impaired 
cognitive function, while other groups have a normal 
cognitive function.
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Figure 1: Graph of serum Aβ-42 level
Discussion
Level data Aβ-42 in serum was tested 
statistically with ANOVA. The results showed that the 
negative control group showed a significantly different 
difference in Aβ-42 levels compared to rats in the 
positive control group. The average level of Aβ-42 in 
the negative control group was 7168.781 while in the 
positive control group 2788.209. The positive control 
group showed a significant difference in Aβ-42 levels 
for the MCT 1 group, MCT 2, and MCT 3, where the 
mean levels of each were 7123.925, 6002.421, and 
6012.389. Between the MCT group receiving different 
doses, there are no differences, and the mean results 
of Aβ-42 are significant (Table 1).
Table 2: Average Y-maze value between groups
Group Mean±SD p
Negative control (K−) 76.42 ± 5.40 0.000
Positive control (K+) 41.25 ± 7.09
Dose 1 71.91 ± 5.20
Dose 2 69.26 ± 10.57
Dose 3 70.11 ± 4.97
The Y-maze test results also showed a 
negative control group, MCT 1, MCT 2, and MCT 3, 
having alternation percentage values above 50% and a 
positive control group having an alternation percentage 
value of <50%. Comparative test results show that the 
higher the Y-maze value, the higher the serum Aβ-42 
level (Table 2).
Table 3: Comparison of the mean percentage alternation 
between groups
Groups p
K−
K+ 0.000
Dose 1 0.795
Dose 2 0.408
Dose 3 0.531
K+
K− 0.000
Dose 1 0.000
Dose 2 0.000
Dose 3 0.000
Dose 1
K− 0.795
K+ 0.000
Dose 2 0.963
Dose 3 0.991
Dose 2
K− 0.408
K+ 0.000
Dose 1 0.963
Dose 3 1.000
Dose 3
K− 0.531
K+ 0.000
Dose 1 0.991
Dose 2 1.000
Animal experiments before have shown that 
MCT can penetrate the blood-brain barrier and be 
oxidized in astrocytes under ketogenic conditions. 
Hence, MCT can provide a direct or indirect source 
of energy for the brain through the production of 
ketones [1]. Other data indicate the potential for an 
MCT diet to treat neurological disorders, especially 
Alzheimer’s disease. Animal experiments showed that 
the administration of MCT reduced Aβ levels in frontal 
dementia dog brain biopsy and increased mitochondrial 
respiration [14].
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Figure 2: Graph of result Y-maze
Studies of transgenic Alzheimer’s rats given 
a ketogenic diet with MCT supplementation showed 
that after 1 week, there was a significant increase in 
beta-hydroxybutyrate levels. The cognitive function 
and cortical Aβ-42 levels were measured after 
6 weeks of MCT; the results showed that rats that 
received MCT had significantly lower levels of Aβ-42 
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than rats that did not receive MCT supplementation 
but did not show differences in cognitive function in 
the two groups [15].
Recently research has concluded, MCT 
increases brain metabolism by supplying ketones 
without affecting brain glucose utilization. Ketones 
from MCT compensate for brain glucose deficits in 
people with Alzheimer’s directly after ketones reach 
plasma [16]. In this study, the effect of giving MCT 
to the levels of Aβ-42 serum and Y-maze of Sprague 
Dawley rats with neurodegenerative disorders has 
been shown to be significant. This can be seen from 
the comparison of the levels of Aβ-42 in all groups. The 
results of the statistical test showed that there were 
significant differences in the levels of Aβ-42 between 
the positive control group and negative controls. 
However, there were no significant differences between 
the negative control groups and the three treatment 
groups. However, among the three treatment groups, it 
was seen that serum Aβ-42 levels were not significantly 
different.
Conclusion
From the results, it can be concluded that the 
group of rats given MCT has serum Aβ-42 level higher 
than the group of rats that were not given MCT. Serum 
Aβ-42 levels describe beta-amyloid clearance in the 
brain, where if there is an imbalance in production and 
clearance, fractions of beta-amyloid will form oligomers 
that are toxic to brain neurons and buildup of beta-
amyloid oligomers can develop into senile plaques, 
which further worsens cognitive function disorders. The 
greater the level of Aβ-42 in the serum means the better 
the Aβ clearance. This is reflected in the percentage 
value of alternation. The better the clearance, the better 
the cognitive function of rats.
In this research, the value of Y-maze, there 
was a significant difference between the positive 
control group and the negative control group and the 
treatment group. While between the negative control 
group and the treatment, there was no difference in the 
percentage of alternation and in the Aβ-42 serum value, 
there was also a significant difference between the 
positive control group and the negative control group 
and the three treatment groups.
After doing this research, it can be suggested 
that MCT can be an alternative energy source for 
glucose replacement in Alzheimer’s patients so that it 
can slow the progression of the disease.
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